Analysts Offer Insights on Healthcare Companies: Penumbra (PEN) and Disc Medicine (IRON)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Penumbra (PEN – Research Report) and Disc Medicine (IRON – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Penumbra (PEN)
In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Penumbra. The company’s shares closed last Thursday at $351.85.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Penumbra is a Strong Buy with an average price target of $346.31, implying a -0.5% downside from current levels. In a report issued on January 5, Evercore ISI also maintained a Buy rating on the stock with a $340.00 price target.
